Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16417 ↗At a glance
Journal article in British Journal of Pharmacology, 2024. Written by Danni Li and 4 co-authors. Institution: Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbo…. Major MEDLINE topics: Rats, Sprague-Dawley, Aminophenols, Drug Combinations, Pyrazoles. Cited 20 times so far (Crossref); 74 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council, Cystic Fibrosis Foundation, Australian Cystic Fibrosis Research Trust.
Abstract (original language)
Background and Purpose Cystic fibrosis (CF) patients are living longer and healthier due to improved treatments, e.g. cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI), with treatment possibly occurring in pregnancy. The risk of ETI to foetuses remain unknown. Thus the effect of maternally administered ETI on foetal genetic and structural development was investigated. Experimental Approach Pregnant Sprague Dawley rats were orally treated with ETI (6.7 mg·kg −1 ·day −1 elexacaftor + 3.5 mg·kg −1 ·day −1 tezacaftor + 25 mg·kg −1 ·day −1 ivacaftor) for 7 days from E12 to E19. Tissue samples collected at E19 were analysed using histology and RNA sequencing. Histological changes and differentially expressed genes (DEG) were assessed. Key Results No overt structural abnormalities were found in foetal pancreas, liver, lung and small intestine after 7‐day ETI exposure. Very few non‐functionally associated DEG in foetal liver, lung and small intestine were identified using RNA‐seq. 29 DEG were identified in thymus (27 up‐regulated and two down‐regulated) and most were functionally linked to each other. Gene ontology enrichment analysis revealed that multiple muscle‐related terms were significantly enriched. Many more DEG were identified in cortex (44 up‐regulated and four down‐regulated) and a group of these were involved in central nervous system and brain development. Conclusion and Implication Sub‐chronic ETI treatment in late pregnancy does not appear to pose a significant risk to the genetic and structural development of many foetal tissues. However, significant gene changes in foetal thymic myoid cells and cortical neuronal development requires future follow‐up studies to assess the risk to these organs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry & Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia.
- Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
- Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
- Department of Respiratory and Sleep Medicine, Women's and Children's Hospital, North Adelaide, South Australia, Australia.
ORCID profiles: Elena K Schneider-Futschik
Funding
- National Health and Medical Research Council
- Cystic Fibrosis Foundation
- Australian Cystic Fibrosis Research Trust
Cite
APA
Li, D., Donnelley, M., Parsons, D., Habgood, M. D., & Schneider-Futschik, E. K. (2024). Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy. British Journal of Pharmacology. https://doi.org/10.1111/bph.16417
Vancouver
Li D, Donnelley M, Parsons D, Habgood MD, Schneider-Futschik EK. Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy. British Journal of Pharmacology. 2024. doi:10.1111/bph.16417
BibTeX
@article{Li2024,
author = {Li, Danni and Donnelley, Martin and Parsons, David and Habgood, Mark D and Schneider-Futschik, Elena K},
title = {Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16417}
}
EUVIMED